PUBLIC PORTAL

MEDICALLY REVIEWED

The Newest JAK inhibitor for Psoriatic Arthritis: Upadacitinib (Rinvoq)

Share on email
Share on print
Share on whatsapp

The disease burden and current treatment landscape
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease with complex clinical manifestations such as plaque psoriasis, dactylitis and enthesitis. Patients with PsA often experience fatigue, physical function limitations, sleep disturbance, as well as diminished work capacity and social participation. The . . .

Login or Sign Up as a healthcare professional to read the full article.

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading

wrist wraps gear

Commentary: Gear Up! (Part 2)

The disease burden and current treatment landscape Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease with complex clinical manifestations such as plaque psoriasis, dactylitis

Read More »